This UK spin out emerged from UK Defence Laboratories in 2019, having been identified by Ploughshare — a company that finds new and inspiring uses for government inventions — as an innovation which could have potential societal impact.
Backed by UKI2S and other investors in both the public and private sectors, Presymptom’s technology is currently undergoing clinical trials at nine NHS hospitals, as well as two hospitals in the Netherlands. Presymptom is using this support to accelerate product development, support clinical trial activity and allow the company to secure UKCA accreditation and roll-out the technology by mid-2025.